Changes of cytokines and regulatory T cells in renal transplant recipients after switch to the mTOR inhibitor Everolimus. A Single center trial, non-blinded, non-randomized. [Veranderungen des Immunstatus bei nierentransplantierten Patienten nach Umstellung der immunsuppressiven Therapie auf den mTOR Inhibitor Everolimus. Eine nicht-verblindete, nicht-randomisierte, monozentrische Studie.]

Trial Profile

Changes of cytokines and regulatory T cells in renal transplant recipients after switch to the mTOR inhibitor Everolimus. A Single center trial, non-blinded, non-randomized. [Veranderungen des Immunstatus bei nierentransplantierten Patienten nach Umstellung der immunsuppressiven Therapie auf den mTOR Inhibitor Everolimus. Eine nicht-verblindete, nicht-randomisierte, monozentrische Studie.]

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2013

At a glance

  • Drugs Everolimus (Primary) ; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Pharmacodynamics
  • Acronyms Ever-cyto-Treg
  • Most Recent Events

    • 12 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top